GLP-3 Reta Clinical Trial Results and Research Updates

GLP-3 Reta clinical trial results and research updates have become a hot topic among scientists studying obesity and metabolic disease. 

Researchers are intrigued because this experimental peptide targets three hormone receptors and produces remarkable weight loss in early studies. 

This article explores the key findings from phase 1 and phase 2 clinical trials, explains ongoing research programs, and highlights what these results mean for the future of weight‑loss treatments. 

The goal is to give you a clear picture of GLP-3 Reta’s progress using simple language and short paragraphs so the information is easy to understand.

In This Article

• What Are the Results of GLP-3 Reta Clinical Trials?
• How Effective Is GLP-3 Reta Compared to Other Treatments?
• When Will GLP-3 Reta Be Released?
• How Long Does GLP-3 Reta Take to Work?
• Comparing GLP-3 Reta and GLP-2 Tirz
• About Spartan Peptides
• Future Research and Off‑Target Considerations
• Conclusion

What Are the Results of GLP-3 Reta Clinical Trials?

GLP-3 Reta is a triple‑hormone receptor agonist that activates GLP‑1, GIP, and glucagon receptors. Early clinical trials have shown significant weight reduction and metabolic benefits. 

Phase 1 Trial Results

A phase 1 study assessed GLP-3 Reta’s safety in people with type 2 diabetes.  

In this small trial, 72 participants received weekly injections of GLP-3 Reta at varying doses for 12 weeks. Those taking 12 mg lost nearly 10 % of their body weight and saw reductions in HbA1c of about 1.2 percentage points. 

Blood pressure, triglycerides, and LDL cholesterol also improved. The study confirmed that GLP-3 Reta could be administered once a week with a favourable safety profile and dose‑dependent weight loss. 

Although the trial was limited, it set the stage for larger studies by showing that the peptide was well-tolerated and effective at reducing weight and blood sugar.

Phase 2 Clinical Trial Results

In the key phase 2 trial of 338 adults with obesity or overweight, participants were randomised to receive different weekly doses of GLP-3 Reta or placebo for 48 weeks. 

At 24 weeks, the mean weight loss was 17.5 % in the highest dose group compared with 1.6 % in the placebo group. 

By week 48, the weight reduction reached 24.2 % in the 12 mg group and 23.9 % in the 8 mg group. These changes translated to about 58 pounds of weight loss on average, and many participants had not yet plateaued at the end of the trial. 

Improvements were also seen in waist circumference and cardiometabolic markers such as HbA1c, blood pressure, and lipid levels. More than 64 % of participants achieved at least 5 % weight loss, and over 26 % lost 30 % or more of their baseline weight. 

These results suggest that GLP-3 Reta may deliver greater weight loss than current single‑ or dual‑agonist therapies.

Safety and Side Effects

Across phase 1 and phase 2 trials, the most common side effects were gastrointestinal. Participants frequently reported nausea, vomiting, diarrhea, and constipation. 

These side effects were generally mild to moderate in severity and occurred mainly during the dose‑escalation period. 

In the phase 2 study, only 4 % of participants in both the GLP-3 Reta and placebo groups experienced serious adverse events, and heart‑related side effects were rare. 

Some participants had small increases in heart rate that peaked and then declined. 

Importantly, GLP-3 Reta also produced large reductions in liver fat for participants with non‑alcoholic fatty liver disease, with more than 80 % of those on higher doses achieving at least a 70 % relative reduction. 

No significant liver toxicity was observed. Overall, these findings suggest that GLP-3 Reta’s safety profile is comparable to existing incretin therapies.

How Effective Is GLP-3 Reta Compared to Other Treatments?

Many readers ask if GLP-3 Reta is more effective than other weight‑loss peptides like GLP-2 Tirz. 

Phase 2 results show that the highest dose of GLP-3 Reta produced greater weight loss than the typical 15 mg dose of GLP-2 Tirz seen in the SURMOUNT‑1 trial, which resulted in about 22.5 % weight reduction. 

GLP-3 Reta participants lost 24.2 % of their body weight, and some lost up to 31 % in smaller participant reports. 

The enhanced efficacy likely stems from GLP-3 Reta’s triple action, which combines GLP‑1 and GIP receptor agonism with glucagon receptor activation. 

Glucagon receptor engagement may boost energy expenditure and fat burning, leading to larger reductions. However, this potent effect also raises challenges. 

Reports from trial participants mention that some individuals needed to reduce their dose or increase calories due to rapid weight loss and side effects like severe nausea and kidney stones. 

Therefore, while GLP-3 Reta appears more effective in weight reduction, its dosing may require careful management to balance efficacy and tolerability.

When Will GLP-3 Reta Be Released?

GLP-3 Reta is still under investigation and has not received regulatory approval. Following the positive phase 2 results, Eli Lilly launched the TRIUMPH phase 3 program to evaluate long‑term safety and efficacy. 

The program includes several randomized, double‑blind trials—TRIUMPH‑1 through TRIUMPH‑4—that will enroll participants with varying degrees of obesity, type 2 diabetes, obstructive sleep apnea, and osteoarthritis. 

These trials will measure not only weight reduction but also improvements in obesity‑related complications. Clinical trial listings indicate that some phase 3 studies are ongoing, while others are set to start recruitment in 2025. 

If the results confirm the benefits seen in earlier trials, analysts expect that GLP-3 Reta could be submitted for regulatory review in 2026. 

Until then, it remains an investigational product available only for research.

How to Find Results of a Clinical Trial

People often wonder how to locate official trial results. The best sources are peer‑reviewed journals and trusted databases like ClinicalTrials.gov. 

The phase 2 obesity trial for GLP-3 Reta is registered as NCT04881760 and can be searched on ClinicalTrials.gov. 

Summary results and design details are also provided in the New England Journal of Medicine (NEJM) article cited in the investor release. 

Additional analyses and commentary are available through open‑access journals like Health Science Reports, where correspondents break down trial design and outcomes. 

Always rely on primary sources or reputable news releases to ensure accuracy.

How Long Does GLP-3 Reta Take to Work?

GLP-3 Reta begins to show effects quickly. In the phase 2 trial, meaningful weight loss appeared within the first four weeks, with participants losing about 5 % of their body weight. 

Weight reduction continued as doses increased and the treatment period lengthened. By 24 weeks, most participants had achieved at least a 5 % reduction, and many exceeded 10 % or more. 

Full benefits appeared closer to the 48‑week mark, when the highest dose group reached 24.2 % weight loss. 

The peptide’s long half‑life (about six days) allows for once‑weekly dosing, keeping drug levels steady throughout the week. 

Overall, GLP-3 Reta acts faster than many older obesity medications, but its true efficacy unfolds over several months of consistent treatment.

Comparing GLP-3 Reta and GLP-2 Tirz

The question “Which is better, GLP-2 Tirz or GLP-3 Reta?” often arises. GLP-2 Tirz is a dual GIP and GLP‑1 receptor agonist already approved for type 2 diabetes and weight management. It produces robust weight loss—up to 22.5 % at 15 mg—but does not engage the glucagon receptor. 

GLP-3 Reta’s triple action yields slightly greater mean weight reduction (up to 24.2 %). Early reports also suggest that GLP-3 Reta may reduce liver fat more dramatically. 

However, GLP-3 Reta is still undergoing trials and has a higher incidence of rapid weight loss that can lead to side effects like severe nausea and potential kidney stone risk. 

GLP-2 Tirz has a more extensive safety profile because it has been studied and approved for clinical use. 

Choosing which peptide is “better” depends on the research goal: GLP-2 Tirz offers proven efficacy with well‑characterized risks, while GLP-3 Reta promises greater weight loss but requires careful dosing and further research.

About Spartan Peptides

Spartan Peptides supplies research‑grade peptides for weight management, anti‑aging, muscle development, and other health research purposes. 

We provide detailed information about each product’s composition and purity so researchers know what they are ordering. 

Our catalog includes GLP-3 Reta and other weight‑loss peptides like GLP-2 Tirz and GLP-1 Sema for laboratory experiments. When we discuss clinical trials, remember that these compounds are investigational and not meant for self‑administration. Our products are offered solely for scientific study.

Future Research and Off‑Target Considerations

While GLP-3 Reta’s weight‑loss results are impressive, researchers must also explore off‑target effects and long‑term safety. 

Preliminary analyses note increases in heart rate and rare cardiac conduction issues. Case reports describe kidney stones in some participants. 

Future trials will monitor these events and investigate whether adjusting dosing can mitigate risks. The TRIUMPH studies will also evaluate GLP-3 Reta’s impact on obesity‑related conditions such as obstructive sleep apnea and osteoarthritis. 

Additional research will examine whether combining GLP-3 Reta with lifestyle interventions or other medications can enhance outcomes. As with all drugs, balancing efficacy with safety is crucial. 

Scientists must continue to share data through peer‑reviewed publications so that physicians and regulators can make informed decisions.

Conclusion

GLP-3 Reta is a next‑generation weight‑loss peptide that activates three hormone receptors to produce substantial weight reduction and metabolic benefits. 

Phase 2 trials show that participants lost up to 24.2 % of their body weight after 48 weeks, with improvements in blood sugar, blood pressure, and liver fat. 

A phase 1 trial in people with type 2 diabetes also showed significant weight loss and HbA1c reductions. 

These results make GLP-3 Reta one of the most potent investigational obesity therapies to date. Yet rapid weight loss and side effects like nausea and kidney stones highlight the need for careful dosing. 

The ongoing TRIUMPH phase 3 program will determine whether the peptide can safely sustain its benefits across diverse populations. 

Until results are available and regulators grant approval, GLP-3 Reta remains a promising research tool rather than a clinical treatment.

Take the Next Step in Peptide Research

If you are exploring advanced weight‑loss peptides, browse our collection to learn more about GLP-3 Reta, GLP-2 Tirz, and GLP-1 Sema. 

For a deeper dive into current studies on GLP-3 Reta, check out our detailed blog article on this emerging research peptide for weight management.

Spartan Peptides is committed to supplying high‑quality research compounds and educational resources to support your scientific journey.

Sourcing GLP-3(Reta) for Laboratory Research

Researchers seeking to study the mechanisms explored in GLP-3(Reta) clinical trials require research-grade peptide that meets stringent purity standards. Spartan Peptides supplies GLP-3(Reta) at ≥98% purity as confirmed by in-house HPLC and mass spectrometry. Lot-specific certificates of analysis are available on request, documenting the exact purity value and MS confirmation for each batch.

For comparative metabolic research, Spartan Peptides also provides GLP-1(Sema) and GLP-2(Tirz), enabling researchers to study the mechanistic differences between single, dual, and triple receptor agonism in parallel experimental designs. Additional metabolic research peptides including AOD-9604 and MOTS-C expand the range of pathways accessible for study.

Before beginning any laboratory protocol, consult the peptide reconstitution guide for handling best practices and the peptide sourcing guide for supplier evaluation criteria.

Frequently Asked Questions

What are the key findings from GLP-3 Reta Phase 2 clinical trials?

Phase 2 clinical trials for GLP-3(Reta) demonstrated significant dose-dependent weight reduction, with the highest dose groups achieving over 17% mean body weight loss at 24 weeks. The compound also showed improvements in glycemic markers, blood pressure, and lipid profiles in obese adult participants.

How does GLP-3(Reta) compare to GLP-1(Sema) in clinical research?

Phase 2 data suggest GLP-3(Reta) may produce greater absolute weight loss than GLP-1(Sema) at equivalent study durations. GLP-3(Reta)’s triple-agonist mechanism targeting GLP-1, GIP, and glucagon receptors provides a broader metabolic profile than GLP-1 monotherapy. Direct head-to-head Phase 3 comparison data are still emerging.

What are the reported side effects in GLP-3(Reta) clinical trials?

The most commonly reported adverse events were gastrointestinal—including nausea, vomiting, and diarrhea—similar to other GLP-1-class compounds. The incidence and severity were generally dose-dependent and tended to decrease over time as participants acclimated to the treatment.

What Phase 3 endpoints are being studied for GLP-3 Reta?

Phase 3 trials are evaluating long-term weight loss maintenance, cardiovascular outcomes, glycemic control in type 2 diabetes populations, and safety in broader demographic groups. Key endpoints include changes in HbA1c, body weight percentage, waist circumference, and major adverse cardiovascular events.

How does the glucagon receptor component of GLP-3(Reta) contribute to its effects?

Glucagon receptor agonism increases energy expenditure and hepatic glucose output, contributing to additional caloric deficit beyond appetite suppression alone. Research suggests this mechanism may enhance lipid metabolism and augment the weight loss observed with GLP-1 and GIP receptor activation.

Written by the Spartan Research Team

Our team of peptide researchers and biochemists reviews every article for scientific accuracy. Learn more about our team →